GSK Consumer Healthcare Australia
In 2019 GSK and Pfizer merged their consumer health businesses, creating a joint venture called GSK Consumer Healthcare.
|GlaxoSmithKline Consumer Healthcare Australia Pty Ltd||AUS||website|
| GSK Consumer Healthcare
owns 100% of GlaxoSmithKline Consumer Healthcare Australia Pty Ltd
| GlaxoSmithKline Plc
owns 68% of GSK Consumer Healthcare
| Pfizer Inc
owns 32% of GSK Consumer Healthcare
|GlaxoSmithKline Consumer Healthcare Australia Pty Ltd|
This company has been criticised for offensive advertising. In 2010 the Advertising Standards Bureau upheld complaints about a print ad by this company on the grounds that it breached advertising codes. The ad was subsequently discontinued or modified.
[Source 2010][More on Irresponsible Marketing]
In 2013, 2011 and 2010 the Therapeutic Goods Administration's Complaints Resolution Panel upheld complaints about seven ads by this company on the grounds that they breached advertising codes. The Panel requested this company withdraw the ads and not to use representations in the ads again.
[Source 2013][More on Irresponsible Marketing]
According to data released by the Australian Tax Office in Dec 2018, this company was one of 2,159 local and foreign-based companies that paid no tax in Australia in 2016-17. Please note however that companies pay income tax on profits, not revenue (total income). While some companies use tax havens and loopholes to avoid paying their fair share of tax in Australia, other companies that paid no tax have perfectly legitimate reasons.
[Source 2018][More on Finance]
|GSK Consumer Healthcare|
GSK Consumer Healthcare is a joint venture between the consumer health divisions of GSK and Pfizer. Both companies have criticisms and a Shop Ethical rating of 'F'.
[More on Governance]
GSK received the highest score in the Access to Medicine Index 2018, a ranking of the world's largest pharmaceutical companies on their efforts to increase access to medicine in developing countries.
[Source 2018][More on Human Rights]
This company received a SAM Rank of 98/100 in the Pharmaceuticals category of the 2018 SAM Corporate Sustainability Assessment. The index is based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
[Source 2018][More on Sustainability Reporting]
In 2018, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to reduce greenhouse gas emissions and mitigate climate change risk. Responding companies are scored across four key areas: disclosure; awareness; management; and leadership. This company received a CDP Climate Change Score of B.
[Source 2018][More on Climate Change]
In 2018, the Carbon Disclosure Project (CDP) asked companies to provide data about their efforts to manage and govern freshwater resources. Responding companies are scored on six key metrics: transparency; governance & strategy; measuring & monitoring; risk assessment; targets & goals; and value chain engagement. This company received a CDP Water Security Score of B.
[Source 2018][More on Human Rights]
This company received a score of 2.5/100 (retrieved 14-Feb-2018) in the Corporate Information Transparency Index (CITI), a system for evaluating supply chain practices in China, particularly in regards to environmental management and water pollution. Scores are calculated using government compliance data, online monitoring data, and third-party environmental audits, as well as trends in the environmental performance of factories in the company's supply chains.
[Source 2018][More on Habitats]
In 2012 the US Department of Justice settled all charges against this company relating to the improper marketing of its anti nausea drug, Zofran to physicians for use in pregnant women and for paying kickbacks to physicians for using the medication. The company was required to pay US$3b in civil and criminal fines to dismiss the allegations. This does not absolve the company of any legal responsibility for damages or injuries caused by Zofran and many lawsuits have been filed in relation to birth defects and injuries.
[Source 2012][More on Irresponsible Marketing]
This company's type 2 diabetes drug Avandia is linked to severe heart problems. More than 50,000 Avandia lawsuits have been filed in state and federal court across the US, citing GSK's failure to inform patients about potentially life-threatening symptoms, including stroke, heart failure, heart attack, bone fractures, vision loss and death, that have been linked to Avandia treatment. GSK has set aside $6.4 billion to pay for Avandia litigation and settlement costs.
[Source 2016][More on Product Safety]
This company's antidepressant drug Paxil has been linked to serious and severe side effects including increased risk of suicide, birth defects and autism. This led to a number of lawsuits. By 2010, GSK had paid over $1 billion to settle more than 800 claims.
[Source 2016][More on Product Safety]
This company appears on PETA's (People for the Ethical Treatment of Animals, USA) 'Companies That Do Test On Animals' list, signifying that they manufacture products that are tested on animals at some stage of development.
[Source 2018][More on Animal Testing]
In July 2012 GSK was fined $US3 billion for marketing drugs for unauthorised uses, holding back safety data, and cheating the US government's Medicaid program. The US Justice Department said the company misbranded its drugs Paxil and Wellbutrin, while making unbacked claims for its diabetes drug Avandia. The department said GSK targeted the antidepressant Paxil to patients under age 18 when it was approved for adults only, and pushed the drug Wellbutrin for uses it was not approved for, including weight loss and treatment of sexual dysfunction.
[Source 2012][More on Governance]
The Forest 500 identifies, ranks, and tracks the governments, companies and financial institutions worldwide that together could virtually eradicate tropical deforestation. Rankings are based on their public policies and commitments and potential impacts on tropical forests in the context of forest risk commodities (palm oil, soya, beef, leather, timber, and pulp and paper). This company received a score of 2/5.
[Source 2018][More on Forests]
In 2016 Greenpeace East Asia ranked the world's 30 biggest personal care companies on their commitment to eliminating microbeads from their personal care products. The scorecard was based on four main criteria: commitment & transparency, definition, deadline and global application. This company ranked towards the bottom of the scorecard. Microbeads are not retained by wastewater treatment and end up in the ocean where they are a threat to the marine environment.
[Source 2016][More on Oceans]
In 2007, ITUC listed several key multinational having business links with
Burma, including GlaxoSmithKline. [Listed under Information due to age of report]
[Source 2007][More on Human Rights]
Friends of the Earth's 2014 report "Tiny Ingredients, Big Risks" names this company as one of over 200 transnational food companies engaged in nanotechnology research and development, and on their way to commercializing products. New studies are adding to a growing body of scientific evidence indicating nanomaterials may be toxic to humans and the environment.
[Source 2014][More on Product Safety]
In 2016 an advertisement showing in the UK for GlaxoSmithKline's Aquafresh toothpaste brand was banned by the UK Advertising Standard Agency due to bogus claims that it provided '24 Hour Sugar Acid Protection'.
[Source 2016][More on Irresponsible Marketing]
GSK agreed to pay a $750 million settlement in response to criminal and civil complaints against the company. SB Pharmco Puerto Rico Inc., a subsidiary of GlaxoSmithKline, has pled guilty to producing and distributing a number of adulterated drugs, including popular medications Paxil and Avandamet. An investigation of the company's manufacturing practices showed that as many as 20 different drugs were unsafely produced for years at a large plant in Cidra, Puerto Rico. [Listed under Information due to age of court finding]
[Source 2010][More on Product Safety]
This company has been criticised by ActionAid for having subsidiaries in tax havens. One of the main reasons companies have subsidiaries in tax havens is to dodge their taxes. Developing countries lose more to tax dodging than they receive in aid each year.
[Source 2011][More on Finance]
This company is listed on the Federal Contractor Misconduct Database as having 33 instances of misconduct since 1995 amounting to US$8,804 million in penalties. Instances include deceptive marketing, litigation related to its antidepressant Paxil, fraud, antitrust issues and vaccine trial fines.
[Source 2014][More on Governance]
This company appeared seventh on RepRisk's top ten "Most Controversial Companies of 2013". Companies on the list were severely criticised during 2013 by the world's media, governments and NGOs. Criticisms of GSK included conducting unauthorised vaccine trials in India, lawsuits over the health and safety of its products, bribery and fraud in China and USA, and workers rights in India.
[Source 2013][More on Governance]
The Carbon Trust Standard recognises organisations for real carbon reduction. They certify organisations that have measured, managed and genuinely reduced their carbon footprint and committed to making further reductions year on year. This company won their award for 'Best in continuing carbon reduction (2012-13)'.
[Source 2013][More on Climate Change]
As listed on the We Mean Business website, this company has committed to the following climate action initiatives: adopt a science-based emissions reduction target; responsible corporate engagement in climate policy; report climate change information in mainstream reports as a fiduciary duty; improve water security.
[Source 2017][More on Climate Change]
The Female FTSE Board Report 2015 examines the percentage of women on the UK's FTSE 100 boards of directors. This company was one of 41 in the FTSE 100 with at least 25% female directors.
[Source 2015][More on Workers Rights]
The United Nations Global Compact asks companies to embrace, support and enact, within their sphere of influence, a set of 10 values in the areas of human rights, labour standards, the environment, and anti-corruption. However it's non-binding nature has been widely criticised, and many signatory corporations continue to violate the Compact's values.
[Source 2015][More on Sustainability Reporting]
California, the UK and Australia have all enacted legislation requiring companies operating within their borders to disclose their efforts to eradicate modern slavery from their operations and supply chains. Follow the link to see this company's disclosure statement.
[Source 2017][More on Human Rights]
This company received a score of 54.2/100 in the Newsweek Green Ranking 2017, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.
[Source 2017][More on Sustainability Reporting]
This company is listed on the Facing Finance website as a company that manufactures weapons or profits from violations of human rights, pollution, corruption, or international law. Follow link for further details.
The Corporate Research Project's Corporate Rap Sheets are dossiers summarising the most significant crimes, violations and other questionable activities of the world's largest and most controversial companies. Follow link to see this company's Corporate Rap Sheet. "In recent years, GlaxoSmithKline has become known as the company that pays massive amounts to resolve wide-ranging charges brought by U.S. regulators and prosecutors. These included a $750 million payment relating to the sale of adulterated products from a facility in Puerto Rico and a record $3 billion in connection with charges relating to illegal marketing, suppression of adverse safety research results and overcharging government customers. The company also set a record for the largest tax avoidance settlement with the U.S. Internal Revenue Service."
OpenSecrets.org tracks the influence of money on U.S. politics, and how that money affects policy and citizens' lives. Follow link to see this company's record of political donations, lobbying, outside spending and more.
|Company Structure||Wholly-owned subsidiary|
|Address||82 Hughes Ave, Ermington, NSW, 2115, Australia|
|Phone||02 9684 0888|
|Fax||02 9684 1018|
|Freecall||1800 028 533|
Products / BrandsGSK Consumer Healthcare Australia
Eno Digestive Care
Lamisil Foot Care
Nicabate Quit Smoking
Otrivin Cold & Flu
Panadol Pain Relief
Panadol Cold & Flu
Panafen Pain Relief
Sensodyne Dental Floss
Zovirax Lip Care